All In Biotech

Free tool

FAERS Monitor: Membraneblue

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 022278 or its brand name (Membraneblue, Trypan Blue). Reports on generic versions are filed under their own applications.

Reports

34

Serious

32

94% of reports

Hospitalization

1

Death reported

1

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • blindness22
  • toxic anterior segment syndrome21
  • corneal oedema6
  • product quality issue6
  • cerebral infarction3
  • pigmentation disorder3
  • thyroid disorder3
  • condition aggravated2
  • off label use2
  • vision blurred2
  • corneal degeneration1
  • drug interaction1
  • eye disorder1
  • macular fibrosis1
  • macular hole1

Reports by year received

View as table
YearReports
201421
20166
20191
20215
20221

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,125 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
toxic anterior segment syndromeSignal2112153.39266.7238,501
corneal degeneration12569.5371.1639
corneal oedemaSignal61660.9802.68,341
macular fibrosis1914.7132.4227
macular hole1461.466.9114
blindnessSignal22334.2260.76,989
pigmentation disorderSignal3300.7102.0621
thyroid disorderSignal3120.440.9246
cerebral infarctionSignal376.025.8153
product quality issueSignal627.313.2128
eye disorder118.82.74
vision blurred29.02.37
condition aggravated24.11.12
drug interaction13.90.60
off label use21.40.40

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.